Molecular subtypes of high-grade serous ovarian cancer: The holy grail?

Journal of the National Cancer Institute

Volumn 106, Issue 10, 2014, Pages

  Waldron, Levi ^a   Riester, Markus ^b   Birrer, Michael ^c,d  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON REGULATORY FACTOR 7; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTOME; TUMOR MARKER;

CANCER PROGNOSIS; CANCER SURVIVAL; EDITORIAL; EPIGENETICS; FEMALE; GENE EXPRESSION; GENOMICS; GENOTYPE; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; OVARY CANCER; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; TRANSCRIPTOMICS; CYSTADENOCARCINOMA; MORTALITY; NOTE; OVARY TUMOR;

CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; OVARIAN NEOPLASMS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84908520883     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju297     Document Type: Editorial

References (16)

1. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
2. McShane LM, Radmacher MD, Freidlin B, et al. Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics. 2002;18(11):1462-1469.
3. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198-5208.
4. Bonome T, Levine DA, Shih J, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008;68(13):5478-5486.
5. Crijns AP, Fehrmann RS, De Jong S, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009;6(2):e24.
6. Konecny GE, Wang C, Hamidi H, et al. Prognostic and Therapeutic Relevance of Molecular Subtypes in High Grade Serous Ovarian Cancer. J Natl Cancer Inst. 2014; In press.
7. Verhaak RG, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123(1):517-525.
8. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
9. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
10. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22):2783-2790.
11. Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014;25(2):339-345.
12. Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91-101.
13. Waldron L, Haibe-Kains B, Culhane AC, et al. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst. 2014;106(5): In press.
14. Riester M, Wei W, Waldron L, et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014;106 (5); In press.
15. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
16. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.